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Abstract 
Review on Burkitt's lymphoma, with data on clinics, 
and the genes involved. 
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Identity 
Other names: Burkitt's tumor; Malignant 
lymphoma Burkitt's type 
Clinics and pathology 
Phenotype/cell stem origin 
Pan-B antigens positive (CD19, CD20, CD21, CD22 
and CD79a); co-expression of CD10 and Bcl-6. 
TdT-, CD5-, CD23-, Bcl-2- and CD138-; sIgM+. 
The cell of origin is a peripheral IgM+ memory B-
cell (presence of somatic hypermutation of the Ig 
gene). Ki67 expression is close to 100% of 
neoplastic cells. 
Etiology 
Burkitt lymphoma (BL) originates from germinal or 
post-germinal center B cells. The three clinical 
subtypes are: endemic, sporadic and 
immunodeficiency-related. All of these likely arise 
from B cells at different stages of development.  
The development of BL is dependent upon the 
constitutive expression of the MYC proto-oncogene 
located at chromosome 8q24. The transcription of 
MYC protein modulates the expression of target 
genes that regulate many cell processes including 
cell growth, division, metabolism and apoptosis.  
Chronic Epstein-Barr virus (EVB) infection appears 
to play a role in all cases of endemic BL and minority 
of sporadic and immunodeficiency-associated BL 
(Klapproth and Wirth, 2010). 
Epidemiology 
Most common in children (1/3 of lymphomas). 
Endemic BL is mainly confined to equatorial Africa 
where it accounts for 30-50% of all childhood 
cancers diagnosed each year (3-6 cases per 100.000 
children).  
Sporadic variant is mostly seen in the US and 
Western Europe. 30% of pediatric lymphomas and  
3 distinct peaks at around age 10, 40 and in the 
elderly. In all groups, most patients are male with a 
3:1 or 4:1 male to female ratio (Magrath, 2012). 
Clinics 
 African endemic variant usually develops in 
children with a jaw or facial bone tumor; initial 
involvement of the abdomen is less common.  
The primary tumor can spread to mesentery, ovary, 
testis, kidney, breast, and meninges, spreading to 
lymph nodes, mediastinum, and spleen less 
frequently. 
 The non-endemic variant may be associated with 
immunodeficiency states and usually presents with 
abdominal involvement (distal ileum, ciecum, 
mesentery). Presenting symptoms can be related to 
bowel obstruction or gastrointestinal bleeding, 
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mimicking acute appendicitis or intussusception. 
Lymphadenopathy is generally localized.  
The disease is very aggressive and requires prompt 
treatment with appropriate regimens. 
Cytology 
The blast cells in the peripheral blood and bone 
marrow display a basophilic cytoplasm with 
characteristic vacuolization, a picture 
indisinguishable from acute lymphoblastic leukemia 
(ALL) L3 of the FAB classification, which 
represents the leukemic counterpart of BL.  
WHO recognize three different types of Burkitt 
Lymphoma:  
 Classic Burkitt lymphoma: Characterized for the 
monomorphic medium-size blast proliferation, with 
lax chromatin, multiple nucleolis and intense 
basophilic cytoplasm. 
 Plasmablastic Burkitt Lymphoma and Atypical 
Burkitt lymphoma: Cells with nuclear 
pleomorphism and nucleoli of big size but in inferior 
number to the observed in the classic form.  
The three variants, blastic cells can be associated 
with plenty mitotic images. 
Pathology 
The tumor mass demonstrate complete effacement of 
the normal architecture by sheets of atypical 
lymphoid cells.  
 At low power, the tumor has a 'mouth-eaten' 
appearance, often with interspersed areas of 
coagulative necrosis or hemorrhage. High rate of 
proliferation and high rate of apoptotic cell death is 
observed. A classic 'starry-sky' pattern is usually 
present, imparted by numerous benign macrophages 
that have ingested apoptotic tumor cells. The benign 
histiocytes are large with abundant, clear cytoplasm 
and are dispersed throughout of basophilic tumor 
cells. 
 At high power, classically are monomorphic, 
medium-size cells with round nuclei, multiple dark 
nucleoli, and basophilic cytoplasm.  
The related form 'Burkitt-like' lymphoma shows 
intermediate features between diffuse large cell 
lymphoma and BL and probably includes different 
disease entities. It was suggested by the WHO panel 
that only those cases with MYC rearrangement 
and/or a >99% proliferation fraction as demonstrated 
by Ki-67 positivity should be classified as Burkitt-
like lymphoma. 
Treatment 
Aggressive regimens specifically designed for this 
lymphoma must be used.  
Multiple intensive regimens demonstrate excellent 
activity in BL and are composed of doxorubicin, 
alkylators, vincristine, and etoposide combined with 
therapy directed at the eradication and/or  
 
 
prevention of central nervous system disease.  
In patients younger than 60 years of age, including 
those with well-controlled HIV, and those up to 70 
years of age with good baseline functional status, 
CODOX-M is recommended.  
Patients with extensive disease and elevated LDH, 2 
cycles each of R-CODOX-M and R-IVAC can be 
used.  
For patients with low-risk disease (a single site of 
disease and normal LDH) 3 cycles of R-CODOX-M.  
For patients with preexisting organ dysfunction, or 
significant comorbidities and patients older than 60 
years of age with low-risk disease, DA-REPOCH 
could be considering a great option associated with 
IT therapy or systemic methotrexate upon the 
completion of cycle 6.  
The addition of rituximab to hyper-CVAD may 
improve outcome in adult BL or B-ALL, particularly 
in elderly patients (Castillo et al., 2013; Jacobson 
and LaCasce, 2014; Dozzo et al., 2016). 
Evolution 
Apart from the occasional refractory case, a few 
responsive BL patients will relapse soon after 
treatment completion and generally within the first 6 
months of follow-up.  
Results in refractory/relapsed BL are extremely 
poor, and new options are urgently needed.  
Relapse and progression frequency varies according 
to first-line treatment used.  
In chemoresistant disease cases, experimental 
therapies, due to the globally poor results of 
traditional salvage programs, should be considered 
in all refractory or relapsed cases. 
Prognosis 
If treated promptly with appropriate regimens the 
majority of patients can be cured. 
Cytogenetics 
Cytogenetics morphological 
The molecular hallmark of BL is the translocation of 
the MYC proto-oncogene to the Ig heavy or 1 light 
chain genes, leading to constitutive MYC activation. 
In classic BL, either endemic type or sporadic type, 
90-95% of Ig loci are involved, 85% for t(8:14)/ IgH-
MYC, 10% for t(8;22)(q24;q11)  /Ig-lambda /MYC 
and approximately 5% for t(2;8)(p12;q24) /Ig-
kappa/MYC.  
 In the Burkitt-like form there are at least 3 
cytogenetic categories: one with an 8q24/MYC 
translocation, one with an 8q24 and 18q21/ BCL2 
translocation and another with "miscellaneous" 
rearrangements, frequently including an 18q21 break 
(Bellan et al., 2005). 
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Additional anomalies 
Recurrent chromosome aberrations associated with 
the 8q24 translocations include 1q21-25 
duplications, deletions of 6q11-14, 17p deletions and 
trisomy 12, +7, +8 and +18. 





MYC functions as a transcriptional regulator. MYC 
binds to MAX that is an obligate heterodimeric 
partner for MYC in mediating its functions.  
The MYC-MAX complex is a potent activator of 
transcription. Thousands of MYC target genes have 
been identified. Genes targeted by MYC include 
mediators of metabolism, biosynthesis, and cell 




Alternatively: IGK, located in 2p11.2 or IGL, 
located in 22q11.22 




Constitutive expression of MYC is crucial for the 
pathogenesis of BL, this protein being a key 
transcriptional regulator, controlling cell 
proliferation, differentiation and death.  
The deregulated expression of MYC, caused by the 
8q24 translocations, is achieved through multiple 
mechanisms: a) juxtaposition to regulatory elements 
of the Ig loci, b) mutations in the MYC 5' regulatory 
regions and, c) aminoacid substitutions occurring in 
exon 2, making the MYC transactivation domain less 
susceptible to modulation (Hecht and Aster, 2000).  
Additional gene alterations include the following: 
truncating mutations of ARID1A and amplification 
of MCL1; point mutations of LRP6; truncating 
alterations of LRP1B, PTPRD, PTEN, NOTCH1, 
and ATM; amplifications of RAF1, MDM4, MDM2, 
KRAS, IKBKE, and CDK6; deletion of CDKN2A; 
overexpression ofMIR17HG; activating mutations 
of TCF3 and/or inactivating mutations of its negative 
regulator ID3; and CCND3 activating mutations 
(Havelange et al., 2016). 
 
References 
Bellan C, Lazzi S, Hummel M, Palummo N, de Santi M, 
Amato T, Nyagol J, Sabattini E, Lazure T, Pileri SA, Raphael 
M, Stein H, Tosi P, Leoncini L. Immunoglobulin gene 
analysis reveals 2 distinct cells of origin for EBV-positive 
and EBV-negative Burkitt lymphomas. Blood. 2005 Aug 
1;106(3):1031-6 
Castillo JJ, Winer ES, Olszewski AJ. Population-based 
prognostic factors for survival in patients with Burkitt 
lymphoma: an analysis from the Surveillance, 
Epidemiology, and End Results database. Cancer. 2013 
Oct 15;119(20):3672-9 
Gaidano G. Molecular genetics of malignant lymphoma. In: 
Fo R (ed): Reviews in clinical and experimental hematology. 
Forum Service Editore, Genova and Martin Dunitz, London,. 
1997.  Catalogue of chromosome aberrations in cancer (5th 
edition).  Mitelmam F ed Wiley Liss, New York. 1994. 
Gibbs RF. The present and future medicolegal importance 
of record keeping in anesthesia and intensive care: the case 
for automation J Clin Monit  1989 Oct;5(4):251-5 
Harris NL, Jaffe ES, Diebold J, Flandrin G, Muller-Hermelink 
HK, Vardiman J, Lister TA, Bloomfield CD. World Health 
Organization classification of neoplastic  diseases of the 
hematopoietic and lymphoid tissues: report of the Clinical 
Advisory Committee meeting-Airlie House, Virginia, 
November 1997 J Clin Oncol  1999 Dec;17(12):3835-49 
Havelange V, Pepermans X, Ameye G, Théate I, Callet-
Bauchu E, Barin C, Penther D, Lippert E, Michaux L, 
Mugneret F, Dastugue N, Raphaül M, Vikkula M, Poirel HA. 
Genetic differences between paediatric and adult Burkitt 
lymphomas Br J Haematol  2016 Apr;173(1):137-44 
Hecht JL, Aster JC. Molecular biology of Burkitt's lymphoma 
J Clin Oncol  2000 Nov 1;18(21):3707-21 
Jacobson C, LaCasce A. How I treat Burkitt lymphoma in 
adults Blood  2014 Nov 6;124(19):2913-20 
Klapproth K, Wirth T. Advances in the understanding of 
MYC-induced lymphomagenesis Br J Haematol  2010 
May;149(4):484-97 
Kornblau SM, Goodacre A, Cabanillas F. Chromosomal 
abnormalities in adult non-endemic Burkitt's lymphoma and 
leukemia: 22 new reports and a review of 148 cases from 
the literature Hematol Oncol  1991 Mar-Apr;9(2):63-78 
Macpherson N, Lesack D, Klasa R, Horsman D, Connors 
JM, Barnett M, Gascoyne RD. Small noncleaved, non-
Burkitt's (Burkit-Like) lymphoma: cytogenetics predict  
outcome and reflect clinical presentation J Clin Oncol  1999 
May;17(5):1558-67 
Mohamed AN. MYC (MYC proto-oncogene, bHLH 
transcription factor) Atlas Genet Cytogenet Oncol 
Haematol. in press. On line version : 
http://AtlasGeneticsOncology.org/Genes/MYCID27.html 
Polito P, Cilia AM, Gloghini A, Cozzi M, Perin T, De Paoli P, 
Gaidano G, Carbone A. High frequency of EBV association 
with non-random abnormalities of the chromosome region 
1q21-25 in AIDS-related Burkitt's lymphoma-derived cell 
lines Int J Cancer  1995 May 4;61(3):370-4 
 
 
Schlegelberger B, Zwingers T, Harder L, Nowotny H, 
Siebert R, Vesely M, Bartels H, Sonnen R, Hopfinger G, 
Nader A, Ott G, Müller-Hermelink K, Feller A, Heinz R. 
Clinicopathogenetic significance of chromosomal 
abnormalities in patients with blastic peripheral B-cell 
lymphoma Kiel-Wien-Lymphoma Study Group  Blood 






Atlas Genet Cytogenet Oncol Haematol. 2019; 23(7) 193 
 
Siebert R, Matthiesen P, Harder S, Zhang Y, Borowski A, 
Zühlke-Jenisch R, Metzke S, Joos S, Weber-Matthiesen K, 
Grote W, Schlegelberger B. Application of interphase  
fluorescence in situ Hybridization for the detection of the 
Burkitt translocation t(8;14)(q24;q32) in B-cell lymphomas 
Blood  1998 Feb 1;91(3):984-90 
This article should be referenced as such: 
Juárez Salcedo LM, Corazón Monzón A, Dalia S. 
Burkitt's lymphoma (BL). Atlas Genet Cytogenet Oncol 
Haematol. 2019; 23(7):190-193. 
